<DOC>
	<DOCNO>NCT00103766</DOCNO>
	<brief_summary>The purpose study assess benefit patient empyema complicate parapneumonic effusion ( CPE ) use daily versus twice daily Alteplase regimen two different dose strategy compare saline placebo .</brief_summary>
	<brief_title>Alteplase Treatment Empyema Complicated Parapneumonic Effusion</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled pilot study . Patients empyema complicate parapneumonic effusion felt require fibrinolytic therapy consider study enrollment . Enrolled patient randomize one five potential treatment arm ( saline placebo , 4 mg daily , 4 mg twice daily , 10 mg daily , 10 mg twice daily ) double-blinded manner .</detailed_description>
	<mesh_term>Pleural Effusion</mesh_term>
	<mesh_term>Empyema</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Ability provide write informed consent Age great equal 18 yr Presence empyema CPE Active internal bleeding Pregnancy Prior enrollment study Platelet count le 100,000/mm3 Use warfarin sodium INR great 1.7 Use heparin unless PTT le 1.5 time baseline normal Known neurological disorder Current preexist bleeding dyscrasia Known allergy Alteplase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>Alteplase</keyword>
	<keyword>Empyema</keyword>
	<keyword>Complicated Parapneumonic Effusion</keyword>
</DOC>